200 related articles for article (PubMed ID: 35802036)
1. Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: A case series.
Aledo-Serrano Á; Cabal-Paz B; Gardella E; Gómez-Porro P; Martínez-Múgica O; Beltrán-Corbellini A; Toledano R; García-Morales I; Gil-Nagel A
Epilepsia Open; 2022 Sep; 7(3):525-531. PubMed ID: 35802036
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
[TBL] [Abstract][Full Text] [Related]
3. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
Devinsky O; King L; Schwartz D; Conway E; Price D
Epilepsia; 2021 Jul; 62(7):e98-e102. PubMed ID: 33979451
[TBL] [Abstract][Full Text] [Related]
4. Genetic and clinical features of SCN8A developmental and epileptic encephalopathy.
Kim HJ; Yang D; Kim SH; Kim B; Kim HD; Lee JS; Choi JR; Lee ST; Kang HC
Epilepsy Res; 2019 Dec; 158():106222. PubMed ID: 31675620
[TBL] [Abstract][Full Text] [Related]
5. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
Frampton JE
Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
[TBL] [Abstract][Full Text] [Related]
6. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Knupp KG; Scheffer IE; Ceulemans B; Sullivan J; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Agarwal A; Lock M; Dai D; Farfel GM; Galer BS; Gammaitoni AR; Polega S; Davis R; Gil-Nagel A
Epilepsia; 2023 Jan; 64(1):139-151. PubMed ID: 36196777
[TBL] [Abstract][Full Text] [Related]
7. SCN1B Genetic Variants: A Review of the Spectrum of Clinical Phenotypes and a Report of Early Myoclonic Encephalopathy.
Zhu Z; Bolt E; Newmaster K; Osei-Bonsu W; Cohen S; Cuddapah VA; Gupta S; Paudel S; Samanta D; Dang LT; Carney PR; Naik S
Children (Basel); 2022 Oct; 9(10):. PubMed ID: 36291443
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and genetic spectrum of SCN8A-related disorders, treatment options, and outcomes.
Gardella E; Møller RS
Epilepsia; 2019 Dec; 60 Suppl 3():S77-S85. PubMed ID: 31904124
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and treatment experience of individuals with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE): Findings from an online caregiver survey.
Cutts A; Savoie H; Hammer MF; Schreiber J; Grayson C; Luzon C; Butterfield N; Pimstone SN; Aycardi E; Harden C; Yonan C; Jen E; Nguyen T; Carmack T; Haubenberger D
Seizure; 2022 Apr; 97():50-57. PubMed ID: 35325842
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications.
Johannesen KM; Liu Y; Koko M; Gjerulfsen CE; Sonnenberg L; Schubert J; Fenger CD; Eltokhi A; Rannap M; Koch NA; Lauxmann S; Krüger J; Kegele J; Canafoglia L; Franceschetti S; Mayer T; Rebstock J; Zacher P; Ruf S; Alber M; Sterbova K; Lassuthová P; Vlckova M; Lemke JR; Platzer K; Krey I; Heine C; Wieczorek D; Kroell-Seger J; Lund C; Klein KM; Au PYB; Rho JM; Ho AW; Masnada S; Veggiotti P; Giordano L; Accorsi P; Hoei-Hansen CE; Striano P; Zara F; Verhelst H; Verhoeven JS; Braakman HMH; van der Zwaag B; Harder AVE; Brilstra E; Pendziwiat M; Lebon S; Vaccarezza M; Le NM; Christensen J; Grønborg S; Scherer SW; Howe J; Fazeli W; Howell KB; Leventer R; Stutterd C; Walsh S; Gerard M; Gerard B; Matricardi S; Bonardi CM; Sartori S; Berger A; Hoffman-Zacharska D; Mastrangelo M; Darra F; Vøllo A; Motazacker MM; Lakeman P; Nizon M; Betzler C; Altuzarra C; Caume R; Roubertie A; Gélisse P; Marini C; Guerrini R; Bilan F; Tibussek D; Koch-Hogrebe M; Perry MS; Ichikawa S; Dadali E; Sharkov A; Mishina I; Abramov M; Kanivets I; Korostelev S; Kutsev S; Wain KE; Eisenhauer N; Wagner M; Savatt JM; Müller-Schlüter K; Bassan H; Borovikov A; Nassogne MC; Destrée A; Schoonjans AS; Meuwissen M; Buzatu M; Jansen A; Scalais E; Srivastava S; Tan WH; Olson HE; Loddenkemper T; Poduri A; Helbig KL; Helbig I; Fitzgerald MP; Goldberg EM; Roser T; Borggraefe I; Brünger T; May P; Lal D; Lederer D; Rubboli G; Heyne HO; Lesca G; Hedrich UBS; Benda J; Gardella E; Lerche H; Møller RS
Brain; 2022 Sep; 145(9):2991-3009. PubMed ID: 34431999
[TBL] [Abstract][Full Text] [Related]
13. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
[TBL] [Abstract][Full Text] [Related]
14. Generalized tonic seizures with autonomic signs are the hallmark of SCN8A developmental and epileptic encephalopathy.
Trivisano M; Pavia GC; Ferretti A; Fusco L; Vigevano F; Specchio N
Epilepsy Behav; 2019 Jul; 96():219-223. PubMed ID: 31174070
[TBL] [Abstract][Full Text] [Related]
15. Evaluating fenfluramine hydrochloride as an oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Rev Neurother; 2024 Mar; 24(3):235-249. PubMed ID: 38315124
[TBL] [Abstract][Full Text] [Related]
16. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
17. SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures.
Wang J; Gao H; Bao X; Zhang Q; Li J; Wei L; Wu X; Chen Y; Yu S
BMC Med Genet; 2017 Sep; 18(1):104. PubMed ID: 28923014
[TBL] [Abstract][Full Text] [Related]
18. Influence of age at seizure onset on the acquisition of neurodevelopmental skills in an SCN8A cohort.
Encinas AC; Moore IKM; Watkins JC; Hammer MF
Epilepsia; 2019 Aug; 60(8):1711-1720. PubMed ID: 31335965
[TBL] [Abstract][Full Text] [Related]
19. The phenotypic spectrum of SCN8A encephalopathy.
Larsen J; Carvill GL; Gardella E; Kluger G; Schmiedel G; Barisic N; Depienne C; Brilstra E; Mang Y; Nielsen JE; Kirkpatrick M; Goudie D; Goldman R; Jähn JA; Jepsen B; Gill D; Döcker M; Biskup S; McMahon JM; Koeleman B; Harris M; Braun K; de Kovel CG; Marini C; Specchio N; Djémié T; Weckhuysen S; Tommerup N; Troncoso M; Troncoso L; Bevot A; Wolff M; Hjalgrim H; Guerrini R; Scheffer IE; Mefford HC; Møller RS;
Neurology; 2015 Feb; 84(5):480-9. PubMed ID: 25568300
[TBL] [Abstract][Full Text] [Related]
20. What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice.
Valls Carbó A; Beltrán Á; Sánchez-Miranda Román I; Cabal B; Gómez-Porro P; Aledo-Serrano Á; López Sobrino G; Ayuga F; Gómez Eguilaz M; Gil-Nagel A
Epilepsy Behav; 2024 Feb; 151():109620. PubMed ID: 38194770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
